Currently, there are no FDA-approved pharmacologic treatments for early AMD; for intermediate AMD, AREDS2 supplementation remains recommended to reduce progression risk. There are several unanswered ...

The European Medicines Agency (EMA) has announced its approval of two new biosimilar medications, Afqlir and Opuviz, to treat age-related macular degeneration (ARMD). The active ingredient of both ...

The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug ...

Age-related macular degeneration, the leading cause of vision loss and blindness for Americans 65 and older, is a progressive disease affecting central vision. Over time, faces, book pages and ...

Age-related macular degeneration (AMD) is a major cause of blindness, especially in older adults. A key feature of early AMD is the formation of drusen, clumps of debris made of lipids and proteins ...

Age-related macular degeneration (AMD) is associated with a higher risk for rheumatoid arthritis (RA), according to a study published online Sept. 9 in Scientific Reports. Je Moon Yoon, from ...

So white light is basically all the wavelengths put together. But what you do with research, research has shown that exposure ...

The SALWEEN study showed significant improvements in vision and retinal health1 More than 60% of Asian patients with ...

A recent survey found that the rate of e-cigarette use among South Korean adults has continued to rise. The use of heated ...

A typical early symptom of age-related macular degeneration (AMD) is difficulty performing tasks under low-light conditions and in low-contrast surroundings. Patients may experience gradually ...